Ernexa Therapeutics (NASDAQ:ERNA) & Relay Therapeutics (NASDAQ:RLAY) Financial Contrast

Ernexa Therapeutics (NASDAQ:ERNA) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of current ratings for Ernexa Therapeutics and Relay Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1	1	1	0	2.00
Relay Therapeutics	1	1	10	2	2.93

Ernexa Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 905.36%. Relay Therapeutics has a consensus price target of $25.92, suggesting a potential upside of 38.95%. Given Ernexa Therapeutics’ higher possible upside, research analysts clearly believe Ernexa Therapeutics is more favorable than Relay Therapeutics.

Volatility and Risk

Ernexa Therapeutics has a beta of 2.64, meaning that its share price is 164% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500.

Profitability

This table compares Ernexa Therapeutics and Relay Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Relay Therapeutics	N/A	-42.27%	-38.67%

Earnings & Valuation

This table compares Ernexa Therapeutics and Relay Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580,000.00	8.39	-$14.08 million	($14.35)	-0.21
Relay Therapeutics	$15.35 million	266.28	-$276.48 million	($1.57)	-11.88

Ernexa Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Relay Therapeutics beats Ernexa Therapeutics on 10 of the 14 factors compared between the two stocks.

About Ernexa Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About Relay Therapeutics

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.